Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Breast cancer, female
Trial Type:  Treatment
Treatment/Intervention:  neoadjuvant therapy
Trial Status:  Active
Results 1-25 of 133 for your search:
Start Over
A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: LITE Randomized Pilot Study, NCT00531973
Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: BCP06, NCT01199432
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P0334, NCT01501487
Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: BEST T-01, NCT01849380
Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000513169, WHC-MRI-GU-2006-097, NCT00397761
Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 59
Sponsor: Other
Protocol IDs: M09TNM, 2009-015238-31, NCT01057069
Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: aesa, NCT01647672
Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: Other
Protocol IDs: TENBC, NCT01648608
A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: HBMUFH-101, NCT01907529
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive Breast Cancer Patients
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: RenJiH-BC-002, NCT02221999
Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 20
Sponsor: Other
Protocol IDs: 200803006M, NCT00776724
Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000669882, ICR-CTSU-2008-10017, UM-EPHOS-B, CRUK-08-002, MREC-09-H1208-52, ISRCTN-15004993, EUDRACT-2008-005466-30, EU-21029, GSK-ICR-CTSU-2008-10017, UM-CR-CTSU/2008/10017,EPHOS-B, NCT01104571
Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 102-00-301, NCT01204801
Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: Endostar B-02, CBCRT01, NCT01479036
Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 50
Sponsor: Other
Protocol IDs: KBCSG012, NCT01622361
Pre Operative Trastuzumab in Operable Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TMH Project-982, NCT01785420
Ketorolac in Breast Cancer Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: KBCtrial, NCT01806259
Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: Vitamin D3/377/TMH, TMH project No. 377, NCT01608451
Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20120283, 2012-004319-29, NCT01901146
Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BCSMANC001, NCT01917578
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A011106, NCI-2013-01340, U10CA031946, NCT01953588
A Study of Patient Satisfaction and Safety With Subcutaneously Administered Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML28851, NCT01964391
Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: M13TRT, NCT01996267
Start Over